Innovent Biologics
Suzhou · Founded 2011
About Innovent Biologics
Innovent Biologics, Inc. is a privately held biopharmaceutical company dedicated to developing and manufacturing monoclonal antibodies to be marketed in China and elsewhere around the world. Innovent is funded by Fidelity's venture arm, a prominent investment firm in the US, Lilly Ventures, and Suzhou bioBay. The registered capital is 30 million US Dollars. The founders and senior management team of Innovent have over 70 years of combined work experience in the discovery, development, and manufacture of biologics in the US, Europe, and worldwide and were involved in the launch of such products as Bexxar, Conbercept, Natrecor, Oncorine, Recombivax HB, and others.
Company Facts
- Founded: 2011
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 5,001 – 10,000
- Estimated revenue: $1M – $10M
- Total funding: $1.5B
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: hkg:1801
- Website: innoventbio.com
- Phone: (86)0512-69566088
Industries & Categories
Biopharma, Biotechnology, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/innovent-biologics-26240 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.